ACKR3 and demyelinating disease: In addition, in line with previous studies using a functional ACKR3 antagonist [8], treatment with ACT-1004-1239 was also able to reduce the demyelination induced by the toxic agent cuprizone in mice, emphasizing the pathological role of ACKR3 in preclinical models of demyelinating diseases [6].